ppi inhibitor

ATG5-PPI Inhibitor 17a has an (E)-3-(2-furanmethyl methylene)-2-pyrrolidone core structure. In the in vitro binding test, it blocked the interactions between ATG5-ATG16L1 and ATG5-TECAIR, with IC50 values of 26.92 uM and 16.34 uM respectively.

ATG5-PPI Inhibitor 17g has an (E)-3-(2-furanmethyl methylene)-2-pyrrolidone core structure. In the in vitro binding test, it blocked the interaction between ATG5-ATG16L1 and ATG5-TECAIR, with IC50 values of 6.14 uM and 10.47 uM respectively.

ATG5-PPI Inhibitor 12d has an (E)-3-(2-furanmethyl methylene)-2-pyrrolidone core structure. In in vitro binding experiments, it blocked the interactions between ATG5-ATG16L1 and ATG5-TECAIR, with IC50 values of >100 μM and 17.5 μM, respectively.

ATG5-PPI Inhibitor 17b has a core structure of (E)-3-(2-furylmethylene)-2-pyrrolidinone and blocks the interactions between ATG5–ATG16L1 and ATG5–TECAIR in in vitro binding assays, with IC₅₀ values of 27.43 μM and 14.88 μM, respectively.

ATG5-PPI Inhibitor 17c has a core structure of (E)-3-(2-furylmethylene)-2-pyrrolidinone and blocks the interactions between ATG5–ATG16L1 and ATG5–TECAIR in in vitro binding assays, with IC₅₀ values of 12.78 μM and 12 μM, respectively.

ATG5-PPI Inhibitor 17e has a core structure of (E)-3-(2-furanmethylene)-2-pyrrolidone. In in vitro binding assays, this inhibitor blocks the interactions between ATG5 and ATG16L1, as well as between ATG5 and TECAIR, with an IC50 value of >33 μM for both interactions.

ATG5-PPI Inhibitor 17h features a core structure of (E)-3-(2-furfurylmethylene)-2-pyrrolidone, and it blocks the interactions between ATG5-ATG16L1 and ATG5-TECAIR in in vitro binding assays with an IC₅₀ of >33 μM for both.

ATG5-PPI Inhibitor 27e has a core structure of (E)-3-(2-furfurylmethylene)-2-pyrrolidone, and it blocks the interactions between ATG5-ATG16L1 and ATG5-TECAIR in in vitro binding assays with IC₅₀ values of >33 μM and 17.26 μM, respectively.

ATG5-PPI Inhibitor 27g has an (E)-3-(2-furylmethylene)-2-pyrrolidone core structure and blocks the interactions between ATG5‑ATG16L1 and ATG5‑TECAIR in in vitro binding assays, with IC50 values of 25 μM and 16 μM, respectively.

ATG5-PPI Inhibitor 27a has a core structure of (E)-3-(2-furylmethylene)-2-pyrrolidone and blocks the interactions between ATG5-ATG16L1 and ATG5-TECAIR in in vitro binding assays, with IC50 values of 2.29 μM and 3.68 μM, respectively.

ATG5-PPI Inhibitor 12b possesses a core structure of (E)‑3‑(2‑furanylmethylene)‑2‑pyrrolidinone and blocks the interactions between ATG5‑ATG16L1 and ATG5‑TECAIR in in vitro binding assays, with IC₅₀ values of > 33 μM and 21.29 μM, respectively.

ATG5-PPI Inhibitor 12f has a core structure of (E)-3-(2-furfurylmethylene)-2-pyrrolidone and blocks the interactions between ATG5-ATG16L1 and ATG5-TECAIR in in vitro binding assays, with IC50 values of >33 μM and 19.16 μM, respectively.

Abeprazan hydrochloride (Fexuprazan hydrochloride) is an effective reversible potassium-competitive acid blocker with oral activity, inhibiting H+, K+ -atPase by competitive binding to potassium ions without acid activation. Abeprazan hydrochloride is a proton pump inhibitor (PPI) that acts by reducing gastric acid production and is used to treat gastric acid-related disorders, such as gastroesophageal reflux disease (GERD) and peptic ulcers.

PPI-1019 is an APP (β-amyloid A4) inhibitor for the treatment of neurological disorders and the study of Alzheimer's disease (AD).

ZW4864 (free base) is an orally active and selective β-catenin/B-Cell lymphoma 9 protein-protein interaction (β-catenin/BCL9 PPI) inhibitor, with a K_i value of 0.76 μM and an IC_50 value of 0.87 μM [1]. ZW4864 (free base) also demonstrates good pharmacokinetic properties.

Pantoprazole Sodium Hydrate (BY1023 (sodium hydrate)) is a proton pump inhibitor drug, used for short-term treatment of erosion and ulceration of the esophagus caused by gastroesophageal reflux disease.

Omeprazole (Losec) is a proton pump inhibitor (PPI), Omeprazole(Losec) is a potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor (exosome inhibitor).

Omeprazole Sodium is a proton pump inhibitor(PPI) and suppresses gastric acid secretion. Omeprazole Sodium is a potent neutral sphingomyelinase (N-SMase) inhibitor (exosome inhibitor). Omeprazole Sodium shows competitive inhibition of CYP2C19 activity with a Ki of 2 to 6 μM. Omeprazole Sodium inhibits growth of Gram-positive and Gram-negative bacteria.

Pantoprazole (BY1023) is a proton pump inhibitor used for short-term treatment of erosion and ulceration of the esophagus caused by gastroesophageal reflux disease.

Pantoprazole sodium (Pantecta) is the sodium salt form of a substituted benzimidazole with proton pump inhibitor activity. Pantoprazole sodium is a lipophilic, weak base that crosses the parietal cell membrane and enters the acidic parietal cell canaliculus where it becomes protonated, producing the active metabolite sulfenamide, which forms an irreversible covalent bond with two sites of the H+/K+-ATPase enzyme located on the gastric parietal cell, thereby inhibiting both basal and stimulated gastric acid production.

4-Desmethoxy Omeprazole, the active metabolite of Omeprazole, acts as a proton pump inhibitor (PPI) and demonstrates competitive inhibition of CYP2C19 activity with a Ki of 2 to 6 μM.

IGS-1.76 exhibits pronounced affinity towards hNCS-1 and effectively modulates the interaction between hNCS-1 and Ric8a. Moreover, IGS-1.76 proficiently inhibits the complex formed by human NCS-1 and Ric8a.

Abarelix (PPI 149) is a potent gonadotrophin-releasing hormone (GnRH) antagonist, which is used for prostate cancer treatment.

BRCA1-IN-2 is a cell membrane-crossing BRCA1 protein-protein interaction (PPI) inhibitor with antitumor activity that acts by disrupting the interaction of BRCA1 (BRCT)2 with proteins.